The Impact of ErbB2 on Cancer Progression and Metastasis through Modulation of Tumor and Tumor Microenvironment

  • Valerie Stone Hawthorne
  • Dihua Yu
Part of the TTME book series (TTME, volume 2)


ErbB2 over-expression in cancer cells leads to a variety of biological consequences. These include cell cycle deregulation, increased invasion, altered adhesion, therapeutic resistance, extra-cellular remodeling, increased angiogenesis, abnormal stromal-epithelial interactions, disrupted integrin signaling and increased homing and metastasis. Here, we review the current and past literature to demonstrate how ErbB2 can impact cell-cell, cell-stromal and cell-matrix interactions, further promoting cancer progression. Through understanding the full interactive picture involved in ErbB2-mediated cancer progression, new-targeted therapies may bring promise to the clinic, benefiting patients who have ErbB2 over-expressing cancers.


Breast cancer EGFR family ErbB2 JAK-STAT pathway Oncogene Cyclin D1 Drug resistance E-cadherin 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Muthuswamy, S.K., et al., ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini. Nat Cell Biol, 2001. 3(9): 785–92.CrossRefPubMedGoogle Scholar
  2. 2.
    Yarden, Y., The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer, 2001. 37(Suppl 4): S3–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Negro, A., B.K. Brar, and K.F. Lee, Essential roles of Her2/erbB2 in cardiac development and function. Recent Prog Horm Res, 2004. 59: 1–12.CrossRefPubMedGoogle Scholar
  4. 4.
    Di Fiore, P.P., et al., erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science, 1987. 237(4811): 178–82.CrossRefPubMedGoogle Scholar
  5. 5.
    Olayioye, M.A., et al., ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner. Mol Cell Biol, 1998. 18(9): 5042–51.PubMedGoogle Scholar
  6. 6.
    Riese, D.J., II, et al., The cellular response to neuregulins is governed by complex interactions of the erbB receptor family. Mol Cell Biol, 1995. 15(10): 5770–76.PubMedGoogle Scholar
  7. 7.
    Basu, T., P.H. Warne, and J. Downward, Role of Shc in the activation of Ras in response to epidermal growth factor and nerve growth factor. Oncogene, 1994. 9(12): 3483–91.PubMedGoogle Scholar
  8. 8.
    Gale, N.W., et al., Grb2 mediates the EGF-dependent activation of guanine nucleotide exchange on Ras. Nature, 1993. 363(6424): 88–92.CrossRefPubMedGoogle Scholar
  9. 9.
    Li, N., et al., Guanine-nucleotide-releasing factor hSos1 binds to Grb2 and links receptor tyrosine kinases to Ras signalling. Nature, 1993. 363(6424): 85–88.CrossRefPubMedGoogle Scholar
  10. 10.
    Wilkinson, M.G. and J.B. Millar, Control of the eukaryotic cell cycle by MAP kinase signaling pathways. Faseb J, 2000. 14(14): 2147–57.CrossRefPubMedGoogle Scholar
  11. 11.
    Cobb, M.H. and E.J. Goldsmith, How MAP kinases are regulated. J Biol Chem, 1995. 270(25): 14843–46.CrossRefPubMedGoogle Scholar
  12. 12.
    Fruman, D.A., R.E. Meyers, and L.C. Cantley, Phosphoinositide kinases. Annu Rev Biochem, 1998. 67: 481–507.CrossRefPubMedGoogle Scholar
  13. 13.
    Kisseleva, T., et al., Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene, 2002. 285(1–2): 1–24.CrossRefPubMedGoogle Scholar
  14. 14.
    Aaronson, D.S. and C.M. Horvath, A road map for those who don’t know JAK-STAT. Science, 2002. 296(5573): 1653–55.CrossRefPubMedGoogle Scholar
  15. 15.
    Wang, S.C., et al., Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell, 2004. 6(3): 251–61.CrossRefPubMedGoogle Scholar
  16. 16.
    Slamon, D.J., et al., Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 1989. 244(4905): 707–12.CrossRefPubMedGoogle Scholar
  17. 17.
    Lacroix, H., et al., Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases. Oncogene, 1989. 4(2): 145–51.PubMedGoogle Scholar
  18. 18.
    Voravud, N., et al., Oncogene expression in cholangiocarcinoma and in normal hepatic development. Hum Pathol, 1989. 20(12): 1163–68.PubMedGoogle Scholar
  19. 19.
    Nigawara, K., et al., [Expression of c-H-ras, c-erb B1 and c-erb B2 gene products in human bladder cancer]. Nippon Hinyokika Gakkai Zasshi, 1992. 83(8): 1212–19.PubMedGoogle Scholar
  20. 20.
    Heinmoller, P., et al., HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin. Clin Cancer Res, 2003. 9(14): 5238–43.PubMedGoogle Scholar
  21. 21.
    Falck, V.G. and W.J. Gullick, c-erbB-2 oncogene product staining in gastric adenocarcinoma: an immunohistochemical study. J Pathol, 1989. 159(2): 107–11.CrossRefPubMedGoogle Scholar
  22. 22.
    Shin, I., T. Miller, and C.L. Arteaga, ErbB receptor signaling and therapeutic resistance to aromatase inhibitors. Clin Cancer Res, 2006. 12(3 Pt 2): 1008s–1012s.CrossRefPubMedGoogle Scholar
  23. 23.
    Yu, D., et al., Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol Cell, 1998. 2(5): 581–91.CrossRefPubMedGoogle Scholar
  24. 24.
    Yu, D., et al., Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol. Oncogene, 1998. 16(16): 2087–94.CrossRefPubMedGoogle Scholar
  25. 25.
    Yu, D., et al., Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene, 1996. 13(6): 1359–65.PubMedGoogle Scholar
  26. 26.
    Piccart-Gebhart, M.J., et al., Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med, 2005. 353(16): 1659–72.CrossRefPubMedGoogle Scholar
  27. 27.
    Robert, N., et al., Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol, 2006. 24(18): 2786–92.CrossRefPubMedGoogle Scholar
  28. 28.
    Romond, E.H., et al., Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med, 2005. 353(16): 1673–84.CrossRefPubMedGoogle Scholar
  29. 29.
    Pavelic, Z.P., et al., c-myc, c-erbB-2, and Ki-67 expression in normal breast tissue and in invasive and noninvasive breast carcinoma. Cancer Res, 1992. 52(9): 2597–602.PubMedGoogle Scholar
  30. 30.
    Guy, C.T., et al., Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA, 1992. 89(22): 10578–82.CrossRefPubMedGoogle Scholar
  31. 31.
    Yu, D., et al., Mechanisms of c-erbB2/neu oncogene-induced metastasis and repression of metastatic properties by adenovirus 5 E1A gene products. Oncogene, 1992. 7(11): 2263–70.PubMedGoogle Scholar
  32. 32.
    Lane, H.A., et al., ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol Cell Biol, 2000. 20(9): 3210–23.CrossRefPubMedGoogle Scholar
  33. 33.
    Basso, A.D., et al., Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene, 2002. 21(8): 1159–66.CrossRefPubMedGoogle Scholar
  34. 34.
    Moasser, M.M., et al., The tyrosine kinase inhibitor ZD1839 (“Iressa”) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res, 2001. 61(19): 7184–88.PubMedGoogle Scholar
  35. 35.
    Motoyama, A.B., N.E. Hynes, and H.A. Lane, The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res, 2002. 62(11): 3151–58.PubMedGoogle Scholar
  36. 36.
    Munster, P.N., et al., Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3’-kinase-AKT-dependent pathway. Cancer Res, 2002. 62(11): 3132–37.PubMedGoogle Scholar
  37. 37.
    Neve, R.M., et al., Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells. Oncogene, 2000. 19(13): 1647–56.CrossRefPubMedGoogle Scholar
  38. 38.
    Yakes, F.M., et al., Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res, 2002. 62(14): 4132–41.PubMedGoogle Scholar
  39. 39.
    Lenferink, A.E., et al., ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways. Cancer Res, 2001. 61(17): 6583–91.PubMedGoogle Scholar
  40. 40.
    Lee, R.J., et al., Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Mol Cell Biol, 2000. 20(2): 672–83.CrossRefPubMedGoogle Scholar
  41. 41.
    Keyomarsi, K., et al., Cyclin E and survival in patients with breast cancer. N Engl J Med, 2002. 347(20): 1566–75.CrossRefPubMedGoogle Scholar
  42. 42.
    White, S.L., et al., Cellular responses to ErbB-2 overexpression in human mammary luminal epithelial cells: comparison of mRNA and protein expression. Br J Cancer, 2004. 90(1): 173–81.CrossRefPubMedGoogle Scholar
  43. 43.
    Moody, S.E., et al., Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell, 2002. 2(6): 451–61.CrossRefPubMedGoogle Scholar
  44. 44.
    Muller, W.J., et al., Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell, 1988. 54(1): 105–15.CrossRefPubMedGoogle Scholar
  45. 45.
    Ritch, P.A., S.L. Carroll, and H. Sontheimer, Neuregulin-1 enhances motility and migration of human astrocytic glioma cells. J Biol Chem, 2003. 278(23): 20971–78.CrossRefPubMedGoogle Scholar
  46. 46.
    Wolf-Yadlin, A., et al., Effects of HER2 overexpression on cell signaling networks governing proliferation and migration. Mol Syst Biol, 2006. 2: 54.CrossRefPubMedGoogle Scholar
  47. 47.
    Jothy, S., et al., Adhesion or anti-adhesion in cancer: what matters more? Cancer Metastasis Rev, 1995. 14(4): 363–76.CrossRefPubMedGoogle Scholar
  48. 48.
    D’Souza, B. and J. Taylor-Papadimitriou, Overexpression of ERBB2 in human mammary epithelial cells signals inhibition of transcription of the E-cadherin gene. Proc Natl Acad Sci USA, 1994. 91(15): 7202–06.CrossRefPubMedGoogle Scholar
  49. 49.
    Woodward, T.L., et al., Proliferation of mouse mammary epithelial cells in vitro: interactions among epidermal growth factor, insulin-like growth factor I, ovarian hormones, and extracellular matrix proteins. Endocrinology, 2000. 141(10): 3578–86.CrossRefPubMedGoogle Scholar
  50. 50.
    Shirk, A.J. and R. Kuver, Epidermal growth factor mediates detachment from and invasion through collagen I and Matrigel in Capan-1 pancreatic cancer cells. BMC Gastroenterol, 2005. 5: 12.CrossRefPubMedGoogle Scholar
  51. 51.
    Zhan, L., B. Xiang, and S.K. Muthuswamy, Controlled activation of ErbB1/ErbB2 heterodimers promote invasion of three-dimensional organized epithelia in an ErbB1-dependent manner: implications for progression of ErbB2-overexpressing tumors. Cancer Res, 2006. 66(10): 5201–08.CrossRefPubMedGoogle Scholar
  52. 52.
    Gusterson, B.A., et al., Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol, 1992. 10(7): 1049–56.PubMedGoogle Scholar
  53. 53.
    Jarvinen, T.A., et al., Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br J Cancer, 1998. 77(12): 2267–73.PubMedGoogle Scholar
  54. 54.
    Albanell, J., F. Rojo, and J. Baselga, Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839. Semin Oncol, 2001. 28(5 Suppl 16): 56–66.CrossRefPubMedGoogle Scholar
  55. 55.
    Pegram, M.D., et al., Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol, 1998. 16(8): 2659–71.PubMedGoogle Scholar
  56. 56.
    Saal, L.H., et al., PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res, 2005. 65(7): 2554–59.CrossRefPubMedGoogle Scholar
  57. 57.
    Konecny, G., et al., Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst, 2003. 95(2): 142–53.PubMedCrossRefGoogle Scholar
  58. 58.
    Stal, O., et al., ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer. Ann Oncol, 2000. 11(12): 1545–50.CrossRefPubMedGoogle Scholar
  59. 59.
    Grunt, T.W., et al., Bidirectional interactions between the estrogen receptor and the cerbB-2 signaling pathways: heregulin inhibits estrogenic effects in breast cancer cells. Int J Cancer, 1995. 63(4): 560–67.CrossRefPubMedGoogle Scholar
  60. 60.
    Yang, Z., C.J. Barnes, and R. Kumar, Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor alpha in breast cancer cells. Clin Cancer Res, 2004. 10(11): 3621–28.CrossRefPubMedGoogle Scholar
  61. 61.
    Benz, C.C., et al., Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat, 1992. 24(2): 85–95.CrossRefPubMedGoogle Scholar
  62. 62.
    Burke, H.B., et al., Predicting response to adjuvant and radiation therapy in patients with early stage breast carcinoma. Cancer, 1998. 82(5): 874–77.CrossRefPubMedGoogle Scholar
  63. 63.
    Pirollo, K.F., et al., p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy. Oncogene, 1997. 14(14): 1735–46.CrossRefPubMedGoogle Scholar
  64. 64.
    Shao, R., et al., Inhibition of nuclear factor-kappaB activity is involved in E1A-mediated sensitization of radiation-induced apoptosis. J Biol Chem, 1997. 272(52): 32739–42.CrossRefPubMedGoogle Scholar
  65. 65.
    Zhou, B.P., et al., HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. J Biol Chem, 2000. 275(11): 8027–31.CrossRefPubMedGoogle Scholar
  66. 66.
    Gearing, A.J., et al., Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature, 1994. 370(6490): 555–57.CrossRefPubMedGoogle Scholar
  67. 67.
    Kajita, M., et al., Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J Cell Biol, 2001. 153(5): 893–904.CrossRefPubMedGoogle Scholar
  68. 68.
    Tan, M., J. Yao, and D. Yu, Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res, 1997. 57(6): 1199–205.PubMedGoogle Scholar
  69. 69.
    Mazumdar, A., et al., Heregulin regulation of urokinase plasminogen activator and its receptor: human breast epithelial cell invasion. Cancer Res, 2001. 61(1): 400–05.PubMedGoogle Scholar
  70. 70.
    Ryan, B.M., et al., Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol, 2006. 17(4): 597–604.CrossRefPubMedGoogle Scholar
  71. 71.
    Heimann, R., et al., Assessment of intratumoral vascularization (angiogenesis) in breast cancer prognosis. Breast Cancer Res Treat, 1998. 52(1–3): 147–58.CrossRefPubMedGoogle Scholar
  72. 72.
    Blackwell, K.L., et al., HER-2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors. Clin Cancer Res, 2004. 10(12 Pt 1): 4083–88.CrossRefPubMedGoogle Scholar
  73. 73.
    Yen, L., et al., Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene, 2000. 19(31): 3460–69.CrossRefPubMedGoogle Scholar
  74. 74.
    Yang, W., et al., ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma. Cancer, 2002. 94(11): 2855–61.CrossRefPubMedGoogle Scholar
  75. 75.
    Finkenzeller, G., et al., Activated Neu/ErbB-2 induces expression of the vascular endothelial growth factor gene by functional activation of the transcription factor Sp 1. Angiogenesis, 2004. 7(1): 59–68.CrossRefPubMedGoogle Scholar
  76. 76.
    Klos, K.S., et al., ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer Res, 2006. 66(4): 2028–37.CrossRefPubMedGoogle Scholar
  77. 77.
    Yang, W., et al., ErbB2 overexpression in human breast carcinoma is correlated with p21Cip1 up-regulation and tyrosine-15 hyperphosphorylation of p34Cdc2: poor responsiveness to chemotherapy with cyclophoshamide methotrexate, and 5-fluorouracil is associated with Erb2 overexpression and with p21Cip1 overexpression. Cancer, 2003. 98(6): 1123–30.CrossRefPubMedGoogle Scholar
  78. 78.
    Traxler, P., et al., AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res, 2004. 64(14): 4931–41.CrossRefPubMedGoogle Scholar
  79. 79.
    Mackay, A., et al., cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells. Oncogene, 2003. 22(17): 2680–88.CrossRefPubMedGoogle Scholar
  80. 80.
    Bon, G., et al., Loss of beta4 integrin subunit reduces the tumorigenicity of MCF7 mammary cells and causes apoptosis upon hormone deprivation. Clin Cancer Res, 2006. 12(11 Pt 1): 3280–87.CrossRefPubMedGoogle Scholar
  81. 81.
    Yoon, S.O., S. Shin, and E.A. Lipscomb, A novel mechanism for integrin-mediated ras activation in breast carcinoma cells: the alpha6beta4 integrin regulates ErbB2 translation and transactivates epidermal growth factor receptor/ErbB2 signaling. Cancer Res, 2006. 66(5): 2732–39.CrossRefPubMedGoogle Scholar
  82. 82.
    Hannigan, G.E., et al., Regulation of cell adhesion and anchorage-dependent growth by a new beta 1-integrin-linked protein kinase. Nature, 1996. 379(6560): 91–96.CrossRefPubMedGoogle Scholar
  83. 83.
    Wu, C., et al., Integrin-linked protein kinase regulates fibronectin matrix assembly, E-cadherin expression, and tumorigenicity. J Biol Chem, 1998. 273(1): 528–36.CrossRefPubMedGoogle Scholar
  84. 84.
    Xie, W., et al., Expression of the integrin-linked kinase (ILK) in mouse skin: loss of expression in suprabasal layers of the epidermis and up-regulation by erbB-2. Am J Pathol, 1998. 153(2): 367–72.PubMedGoogle Scholar
  85. 85.
    Khoury, H., et al., HGF converts ErbB2/Neu epithelial morphogenesis to cell invasion. Mol Biol Cell, 2005. 16(2): 550–61.CrossRefPubMedGoogle Scholar
  86. 86.
    Price-Schiavi, S.A., et al., Expression, location, and interactions of ErbB2 and its intramembrane ligand Muc4 (sialomucin complex) in rat mammary gland during pregnancy. J Cell Physiol, 2005. 203(1): 44–53.CrossRefPubMedGoogle Scholar
  87. 87.
    Pino, V., et al., Membrane mucin Muc4 induces density-dependent changes in ERK activation in mammary epithelial and tumor cells: role in reversal of contact inhibition. J Biol Chem, 2006. 281(39): 29411–20.CrossRefPubMedGoogle Scholar
  88. 88.
    Chiodoni, C., et al., Triggering CD40 on endothelial cells contributes to tumor growth. J Exp Med, 2006. 203(11): 2441–50.CrossRefPubMedGoogle Scholar
  89. 89.
    Muller, A., et al., Involvement of chemokine receptors in breast cancer metastasis. Nature, 2001. 410(6824): 50–56.CrossRefPubMedGoogle Scholar
  90. 90.
    Nagasawa, T., et al., Molecular cloning and characterization of a murine pre-B-cell growth-stimulating factor/stromal cell-derived factor 1 receptor, a murine homolog of the human immunodeficiency virus 1 entry coreceptor fusin. Proc Natl Acad Sci USA, 1996. 93(25): 14726–29.CrossRefPubMedGoogle Scholar
  91. 91.
    Braun, S., et al., ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. Cancer Res, 2001. 61(5): 1890–95.PubMedGoogle Scholar
  92. 92.
    Li, Y.M., et al., Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell, 2004. 6(5): 459–69.CrossRefPubMedGoogle Scholar
  93. 93.
    Cabioglu, N., et al., Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow. Clin Exp Metastasis, 2005. 22(1): 39–46.CrossRefPubMedGoogle Scholar
  94. 94.
    Corsini, C., et al., Stroma cells: a novel target of herceptin activity. Clin Cancer Res, 2003. 9(5): 1820–25.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2008

Authors and Affiliations

  • Valerie Stone Hawthorne
  • Dihua Yu
    • 1
  1. 1.Department of Molecular and Cellular OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations